SI0752246T1 - Use of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl acetamide hydrochloride for the preparation of a medicament for the treatment of inflammatory diseases of the intestine - Google Patents

Use of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl acetamide hydrochloride for the preparation of a medicament for the treatment of inflammatory diseases of the intestine

Info

Publication number
SI0752246T1
SI0752246T1 SI9630475T SI9630475T SI0752246T1 SI 0752246 T1 SI0752246 T1 SI 0752246T1 SI 9630475 T SI9630475 T SI 9630475T SI 9630475 T SI9630475 T SI 9630475T SI 0752246 T1 SI0752246 T1 SI 0752246T1
Authority
SI
Slovenia
Prior art keywords
hydroxypyrrolidin
intestine
medicament
phenyl
ethyl
Prior art date
Application number
SI9630475T
Other languages
English (en)
Slovenian (sl)
Inventor
Andrew Dr. Barber
Christoph Dr. Seyfried
Gerd Bartoszyk
Rudolf Dr. Gottschlich
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SI0752246T1 publication Critical patent/SI0752246T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
SI9630475T 1995-06-28 1996-06-20 Use of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl acetamide hydrochloride for the preparation of a medicament for the treatment of inflammatory diseases of the intestine SI0752246T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19523502A DE19523502A1 (de) 1995-06-28 1995-06-28 Kappa-Opiatagonisten für entzündliche Darmerkrankungen
EP96109915A EP0752246B1 (de) 1995-06-28 1996-06-20 Verwendung von N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl]-2,2-diphenyl-acetamid Hydrochlorid zur Herstellung von Arzneimitteln zur Behandlung von entzündlichen Darmerkrankungen

Publications (1)

Publication Number Publication Date
SI0752246T1 true SI0752246T1 (en) 2002-10-31

Family

ID=7765475

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630475T SI0752246T1 (en) 1995-06-28 1996-06-20 Use of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl acetamide hydrochloride for the preparation of a medicament for the treatment of inflammatory diseases of the intestine

Country Status (26)

Country Link
US (2) US5776972A (xx)
EP (1) EP0752246B1 (xx)
JP (2) JP4415075B2 (xx)
KR (1) KR100501612B1 (xx)
CN (1) CN1119147C (xx)
AR (1) AR004671A1 (xx)
AT (1) ATE214275T1 (xx)
AU (1) AU708699B2 (xx)
BR (1) BR9602915A (xx)
CA (1) CA2179955C (xx)
CO (1) CO4700454A1 (xx)
CZ (1) CZ289805B6 (xx)
DE (2) DE19523502A1 (xx)
DK (1) DK0752246T3 (xx)
ES (1) ES2171577T3 (xx)
HU (1) HU226976B1 (xx)
NO (1) NO309674B1 (xx)
PL (1) PL185537B1 (xx)
PT (1) PT752246E (xx)
RU (1) RU2190401C2 (xx)
SI (1) SI0752246T1 (xx)
SK (1) SK283497B6 (xx)
TR (1) TR199600497A2 (xx)
TW (1) TW430557B (xx)
UA (1) UA51615C2 (xx)
ZA (1) ZA965480B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
ATE235903T1 (de) * 1996-12-02 2003-04-15 Kyorin Seiyaku Kk Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
US6133307A (en) * 1997-04-30 2000-10-17 Warner-Lambert Company Certain benzofuranyl-N-[pyrrolidin-1-YL]-N-methyl-acetamide derivatives useful as opioid agonists
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
WO1999003459A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
AU2003242527B2 (en) * 2002-05-17 2008-10-23 Tioga Pharmaceuticals, Inc. Use of compounds that are effective as selective opiate receptor modulators
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
TWI334349B (en) * 2003-07-04 2010-12-11 Santen Pharmaceutical Co Ltd Pain threshold reduction depressant
CA2544245A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
US7160902B2 (en) * 2003-11-14 2007-01-09 Adolor Corporation Amide derivatives and methods of their use
US7642274B2 (en) 2004-07-02 2010-01-05 Santen Pharmaceutical Co., Ltd. Inhibitor of pain threshold decrease
EP2136801B1 (en) * 2007-03-30 2012-08-29 Tioga Pharmaceuticals, Inc. Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome
JP6138169B2 (ja) * 2012-03-05 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド κオピオイド受容体（ＫＯＲ）アゴニストとしての置換複素環式アセトアミド
MX2016009624A (es) * 2014-01-24 2016-11-08 Cadila Healthcare Ltd Compuestos heterobiciclicos novedosos como agonistas del opioide kappa.
WO2018119108A1 (en) 2016-12-21 2018-06-28 Tioga Pharmaceuticals Inc. Splid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
CA2021817C (en) * 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
JP4415075B2 (ja) 2010-02-17
DK0752246T3 (da) 2002-05-13
AR004671A1 (es) 1999-03-10
KR100501612B1 (ko) 2005-10-12
UA51615C2 (uk) 2002-12-16
PL314996A1 (en) 1997-01-06
NO962720L (no) 1996-12-30
ATE214275T1 (de) 2002-03-15
US5776972A (en) 1998-07-07
CA2179955A1 (en) 1996-12-29
TR199600497A2 (tr) 1997-01-21
PL185537B1 (pl) 2003-05-30
JP5308056B2 (ja) 2013-10-09
NO309674B1 (no) 2001-03-12
SK283497B6 (sk) 2003-08-05
HU226976B1 (en) 2010-04-28
JP2008201794A (ja) 2008-09-04
CZ289805B6 (cs) 2002-04-17
EP0752246A2 (de) 1997-01-08
CZ186696A3 (en) 1997-01-15
ZA965480B (en) 1997-01-27
CA2179955C (en) 2008-10-07
US5977161A (en) 1999-11-02
CN1145781A (zh) 1997-03-26
TW430557B (en) 2001-04-21
DE19523502A1 (de) 1997-01-02
PT752246E (pt) 2002-09-30
HUP9601798A1 (hu) 1998-03-30
KR970000230A (ko) 1997-01-21
AU5616296A (en) 1997-01-09
CN1119147C (zh) 2003-08-27
EP0752246A3 (de) 1997-02-26
NO962720D0 (no) 1996-06-27
EP0752246B1 (de) 2002-03-13
RU2190401C2 (ru) 2002-10-10
BR9602915A (pt) 1998-04-22
JPH0920659A (ja) 1997-01-21
SK84396A3 (en) 1997-04-09
DE59608861D1 (de) 2002-04-18
CO4700454A1 (es) 1998-12-29
ES2171577T3 (es) 2002-09-16
AU708699B2 (en) 1999-08-12

Similar Documents

Publication Publication Date Title
SI0752246T1 (en) Use of N-methyl-N-((1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)-ethyl)-2,2-diphenyl acetamide hydrochloride for the preparation of a medicament for the treatment of inflammatory diseases of the intestine
AU6154199A (en) Apparatus and method for diagnosis and therapy of electrophysiological disease
HUP0203198A3 (en) Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
AU2001262943A1 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
GB2303064B (en) Medicament for nasal administration
NO20004915D0 (no) Transdermalt terapeutisk system som inneholder en D2-agonist for behandling av Parkinson-syndromet, og en fremgangsmÕte for dens fremstilling
BR9506400A (pt) Método e aparelho para administrar droga a um paciente
HUP0201711A2 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same
HK1047231A1 (en) Oral pharmaceutical forms of administration with adelayed action with tramadol
HU9802422D0 (en) Substituted isoquinoline-3-carboxamide derivatives, process for producing them and their medical use
AU2001283563A1 (en) Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
HUP0201623A2 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
BR9609645A (pt) Inalador para a administração de medicamentos a partir de embalagens de ampola
EE04417B1 (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
AU2429895A (en) A method of modifying angiotensin receptor activity for treatment of premenstrual syndrome and mediation of pain
HUP0301333A2 (hu) Gyógyszer szuperdezintegráns, eljárás az előállítására és alkalmazása
WO1999004772A3 (en) Use of levobupivacaine
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
HK1018211A1 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/dydrogen exchanger and a medicament for the treatment of cardiovascular diseases.
NO307048B1 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l
AU2000265525A1 (en) Medicament for treating intestinal diseases
AU3660700A (en) N-(2-(4-aminophyl)ethyl)-2,3-dihydro-1,4-benzodioxine-2-met hanamine, production and therapeutic use thereof
PL321630A1 (en) Application of melantonine for treting patients suffering from drug dependence
AU3945501A (en) Apparatus for dosage of medicaments